ADVFN
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Moleculin Biotech Inc

Moleculin Biotech Inc (MBRX)

0.6287
-0.0014
(-0.22%)
0.625
-0.0037
( -0.59% )

Moleculin Biotech Inc (MBRX) Quote

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
0.625
( -0.59% )
Bid
0.6287
Ask
0.64
Volume
7,933
0.00 Day's Range 0.00
0.25 52 Week Range 4.707
Market Cap
Previous Close
0.6287
Open
-
Last Trade
8
@
0.625
Last Trade Time
04:54:35
Financial Volume
-
VWAP
-
Average Volume (3m)
4,610,911
Shares Outstanding
14,127,494
Dividend Yield
-
PE Ratio
-0.41
Earnings Per Share (EPS)
-1.54
Revenue
-
Net Profit
-21.76M

About Moleculin Biotech Inc

Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Mod... Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Moleculin Biotech Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MBRX. The last closing price for Moleculin Biotech was $0.63. Over the last year, Moleculin Biotech shares have traded in a share price range of $ 0.25 to $ 4.707.

Moleculin Biotech currently has 14,127,494 shares outstanding. The market capitalization of Moleculin Biotech is $8.88 million. Moleculin Biotech has a price to earnings ratio (PE ratio) of -0.41.

MBRX Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0021-0.3348748206030.62710.7250.496106577810.58270635CS
4-0.055-8.088235294120.680.72620.25136351730.4490977CS
12-0.475-43.18181818181.11.14440.2546109110.48319195CS
26-1.165-65.08379888271.793.64990.2550036511.12514548CS
52-3.625-85.29411764714.254.7070.2524857111.1378484CS
156-25.175-97.577519379825.829.10.259202572.18994981CS
260-14.825-95.954692556615.45131.70.2597987218.51464656CS

MBRX - Frequently Asked Questions (FAQ)

What is the current Moleculin Biotech share price?
The current share price of Moleculin Biotech is $ 0.625
How many Moleculin Biotech shares are in issue?
Moleculin Biotech has 14,127,494 shares in issue
What is the market cap of Moleculin Biotech?
The market capitalisation of Moleculin Biotech is USD 8.88M
What is the 1 year trading range for Moleculin Biotech share price?
Moleculin Biotech has traded in the range of $ 0.25 to $ 4.707 during the past year
What is the PE ratio of Moleculin Biotech?
The price to earnings ratio of Moleculin Biotech is -0.41
What is the reporting currency for Moleculin Biotech?
Moleculin Biotech reports financial results in USD
What is the latest annual profit for Moleculin Biotech?
The latest annual profit of Moleculin Biotech is USD -21.76M
What is the registered address of Moleculin Biotech?
The registered address for Moleculin Biotech is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Moleculin Biotech website address?
The website address for Moleculin Biotech is www.moleculin.com
Which industry sector does Moleculin Biotech operate in?
Moleculin Biotech operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GTIGraphjet Technology
$ 0.1426
(95.34%)
98.4M
NUWENewellis Inc
$ 11.80
(71.14%)
1.47M
TNFATNF Pharmaceuticals Inc
$ 0.1585
(49.25%)
14.55M
GAMEGameSquare Holdings Inc
$ 2.10
(39.07%)
2.22M
DTSTData Storage Corporation
$ 4.51
(33.43%)
667.38k
SLNHSoluna Holdings Inc
$ 0.449
(-41.24%)
1.18M
CYCCCyclacel Pharmaceuticals Inc
$ 7.94
(-35.60%)
85.92k
XELBXcel Brands Inc
$ 1.16
(-28.40%)
278
PCLAPicoCELA Inc
$ 0.64
(-20.99%)
98.32k
GANXGain Therapeutics Inc
$ 1.41
(-17.06%)
1.53k
GTIGraphjet Technology
$ 0.1426
(95.34%)
98.4M
IXHLIncannex Healthcare Ltd
$ 0.4225
(24.26%)
17.06M
TNFATNF Pharmaceuticals Inc
$ 0.1585
(49.25%)
14.55M
NCNANuCana PLC
$ 0.0505
(0.60%)
2.57M
GAMEGameSquare Holdings Inc
$ 2.10
(39.07%)
2.22M

MBRX Discussion

View Posts
TheSprinx TheSprinx 2 days ago
Buckle up 
👍️0
TheSprinx TheSprinx 2 days ago
We are about to go Parabolic here. Trading will be halted and new SP will open in the $2-$3 range and then it will blast towards $10 Imho
👍️0
gail gail 7 days ago
mm arcx moved their big….

..

ask down to .587, someone started to take them out and then they moved lower with another order, but if we take out the biggy, its on!!
👍️0
gail gail 7 days ago
wall at .60 to the tune of $117,600, yipes.
👍️0
gail gail 7 days ago
burst of buys hitting now, lets do this!!
👍️0
gail gail 7 days ago
its inching up now, im hoping for a…



run like it did a while back. the recent volume is similar to that last big runner.
👍 1
BadCuda BadCuda 7 days ago
Mid day pullback , buying for the flip to .70 
👍️0
gail gail 7 days ago
thx for the update there.
👍️ 1
INV4 INV4 7 days ago
Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

July 9, 2025

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in the country of Georgia has approved its Clinical Trial Application (CTA) to conduct its pivotal Phase 2B/3, multi-center, randomized, double-blind, placebo-controlled, adaptive design study of Annamycin in combination with cytarabine (also known as “Ara-C” and for which the combination of Annamycin and Ara-C is referred to as “AnnAraC”) for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy (R/R AML). This Phase 3 “MIRACLE” trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation) is a global approval trial, including sites in the US, Europe and the Middle East. Additionally, the Company expects the first patient to be treated in Georgia to occur by the end of August, if not sooner.

“Building upon our recently announced CTA approval in the European Union (EU) from the European Medicines Agency (EMA), RAMPA approval of the MIRACLE trial protocol represents another important milestone and bolsters our ongoing enrollment efforts,” said Walter Klemp, Chairman and CEO of Moleculin. “We expect to add 16 additional sites in Europe and the US to MIRACLE by the end of August. This will build to more than 30 sites by year-end for Part A of the MIRACLE. Adding to this progress, our recruitment in Part A of MIRACLE has hit seven subjects treated and one in screening with just our first site in Ukraine. All of this, importantly, supports our goal to report initial data on the first 45 subjects from Part A in the second half of 2025.”

Mr. Klemp continued, “This early success in recruitment underscores the capability of our clinical sites, with the first ten screened subjects within just three months of site activation, and it showcases the commitment of ARENSIA Exploratory Medicine’s research clinic in Kyiv, Ukraine (ARENSIA). We are grateful for the continued international regulatory collaboration for this trial and believe it reflects the potential demand for Annamycin and the significant unmet need for better treatment options for R/R AML patients, especially venetoclax regimen failures where the outcomes from currently available therapies are considered dismal. Our team remains focused on driving enrollment and advancing this important program forward.”

The MIRACLE study is a Phase 2B/3 clinical trial whereby data from the 2B portion will be combined with the Phase 3 portion for purposes of measuring its primary efficacy endpoint. MIRACLE is subject to appropriate future filings with and potential additional feedback from the FDA and their foreign equivalents, utilizes an adaptive design whereby the first 75 to 90 subjects will be randomized (1:1:1) in Part A of the trial to receive high dose cytarabine (HiDAC) combined with either placebo, 190 mg/m2 of Annamycin, or 230 mg/m2 of Annamycin, which Annamycin doses were specifically recommended by the FDA in the Company’s end of Phase 1B/2 meeting.

The protocol for the MIRACLE trial allows for the unblinding of preliminary primary efficacy data (Complete Remission or CR) and safety/tolerability of the three arms at 45 subjects, in addition to the conclusion of Part A (at 75 to 90 subjects). The first early unblinding will yield 30 subjects treated with Annamycin (190mg/m2 and 230 mg/m2) in combination with HiDAC and 15 subjects treated with just HiDAC plus placebo. The Company expects to reach the first unblinding (45 subjects) in the second half of 2025, in addition to the second unblinding, which is expected in the first half of 2026. This accelerated estimated timeline is due in part to the positive response the Company received in meetings during December with potential investigators regarding recruitment for the trial.

As previously announced with regard to the EU, the clinical trial approval with EMA was granted under the condition that the Company present results of appropriate nonclinical GLP studies before initiating the Phase 3 portion (Part B) of the study. Results will be submitted as a substantial modification to the existing approved CTA.

For Part B of the trial, approximately 220 additional subjects will be randomized to receive either HiDAC plus placebo or HiDAC plus the optimum dose of Annamycin (randomized 1:1). The selection of the optimum dose will be based on the overall balance of safety, pharmacokinetics and efficacy, consistent with the FDA’s new Project Optimus initiative.

Patient dosing has commenced, and the initial data readout is on track for the second half of 2025. For more information about the MIRACLE trial, visit clinicaltrials.gov and reference identifier NCT06788756. Additionally, the clinical trial in the EU is on euclinicaltrials.eu and the reference identifier there is 2024-518359-47-00.

Annamycin, also known by its non-proprietary name of naxtarubicin, currently has Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory acute myeloid leukemia, in addition to Orphan Drug Designation for the treatment of soft tissue sarcoma. Furthermore, Annamycin has Orphan Drug Designation for the treatment of relapsed or refractory acute myeloid leukemia from the EMA.

About ARENSIA Exploratory Medicine GmbH
ARENSIA Exploratory Medicine GmbH is a German operator of proprietary hospital-based research clinics, dedicated to performing complex clinical trials with novel molecules, involving patients across numerous disease areas. ARENSIA aims to speed up patients’ access to innovative therapies by collaborating with cutting-edge pharmaceutical companies and currently operates 13 state-of-the-art research clinics across the United States of America and Eastern Europe.

For more information about ARENSIA and its clinical operations, please visit www.arensia.com.

About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

https://ih.advfn.com/stock-market/NASDAQ/moleculin-biotech-MBRX/stock-news/96399536/moleculin-expands-phase-3-miracle-clinical-trial-i

$MBRX 💹
👍️0
gail gail 7 days ago
boomage!!!!
👍️0
gail gail 7 days ago
here we go, so far in premarket!
👍️0
gail gail 7 days ago
grabbed some premarket.
👍️0
glenn1919 glenn1919 1 week ago
MBRX..............................................................https://stockcharts.com/h-sc/ui?s=MBRX&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 2 months ago
MBRX under $2
👍️0
Monksdream Monksdream 3 months ago
MBRX under $2
👍️0
glenn1919 glenn1919 3 months ago
MBRX.............................https://stockcharts.com/h-sc/ui?s=MBRX&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 4 months ago
Watching just need those offering shares to be gobbled up above $1.07 holds above a few days .... 6.5m shares of common stock in a concurrent private placement (together with the registered direct offering, the "Offering") at a combined purchase price of 1.07per share and accompanying warrants. The warrants issued pursuant to the concurrent private placement will have an exercise price of 1.07per share,..
👍️0
georgie18 georgie18 4 months ago
MBRX...$1.30...HOD...🥳...Off my $1.04 Alert...

georgie18

Member Level
Re: None

Monday, March 24, 2025 7:45:20 PM

Post#
677861
of 677941
MBRX...$1.04...🥳...https://schrts.co/efYmehcr ...MB-107 trial. 11/13/23- Positive interim data. Final data read-out in Q3 2024 & initiate 1st line STS study in Q3 '24. 3/21/25- CSR finalized but not yet submitted. Final data to be presented by the end of April 2025. ...

https://s3.amazonaws.com/sec.irpass.cc/2705/0001437749-25-008751.pdf
👍️0
georgie18 georgie18 4 months ago
MBRX...$1.04...🥳...https://schrts.co/efYmehcr ...MB-107 trial. 11/13/23- Positive interim data. Final data read-out in Q3 2024 & initiate 1st line STS study in Q3 '24. 3/21/25- CSR finalized but not yet submitted. Final data to be presented by the end of April 2025. ...

https://s3.amazonaws.com/sec.irpass.cc/2705/0001437749-25-008751.pdf
👍️0
glenn1919 glenn1919 5 months ago
MBRX...........................................................https://stockcharts.com/h-sc/ui?s=MBRX&p=W&b=5&g=0&id=p86431144783
👍️0
PinkPennies PinkPennies 5 months ago
MBRX withdrawal of offering https://ih.advfn.com/stock-market/NASDAQ/moleculin-biotech-MBRX/stock-news/95500799/form-rw-registration-withdrawal-request
👍️0
Invest-in-America Invest-in-America 5 months ago
MBRX: Indeed!! (It simply had SOARED too hideously, that first day of that news; hopefully now, when their PHASE-3 final results are in, we have an OUTRIGHT CURE for perhaps many types of Cancer.)
👍️0
Gator44 Gator44 5 months ago
MBRX https://ih.advfn.com/stock-market/NASDAQ/moleculin-biotech-MBRX/stock-news/95429160/moleculin-receives-positive-fda-guidance-for-accel
That is no FLUFF pr...
👍️0
Invest-in-America Invest-in-America 5 months ago
MBRX; I sincerely HOPE so, Bro!! (What a VOLATILE casino Wall Street has become, Dude!! Bottom line, as always, be sure to first 'consult' with my TWO personal 'BROKERS', below!! I.e., my charming San Diego's neighbor's lovely DAUGHTER, & my own personal stock broker for many years now, namely, D. HARRY & SONS, PERSONAL FINANCIAL PLANNERS!!)



👍️0
Zardiw Zardiw 5 months ago
#DDAmanda Video: $MBRX: Gain: +257% #1 Early Alert Stock Finder



Z
👍️0
glenn1919 glenn1919 5 months ago
MBRX...........................................................https://stockcharts.com/h-sc/ui?s=MBRX&p=W&b=5&g=0&id=p86431144783
👍️0
Gator44 Gator44 5 months ago
Gapper Monday.... warrants absorbed w/today's vol. ?
👍️0
Invest-in-America Invest-in-America 5 months ago
MBRX: This is iHub's "Invest-in-America" to the MBRX High Seas Fleet --- OPEN FIRE!!! Show Wall Street, and the WORLD, what a REAL PHARMA company is all about!!!

👍️0
Invest-in-America Invest-in-America 5 months ago
MBRX: Maybe not, Dude. (I myself grabbed this at $2.02 --- and COULD have dumped it all for nice profit, within 10-minutes from Open today --- but still holding. YES, we're dealing with the proverbial 'YESTERDAY'S NEWS' here, but we'll see shortly here.)
👍️0
RUSTYJ RUSTYJ 5 months ago
Im late to game as always
👍️0
Invest-in-America Invest-in-America 5 months ago
MBRX: Make that $20+ --- good old classic USA Greenbacks (fluck the stupid Bitcoin) --- by day's end today, Homeboys!!!
👍️0
Invest-in-America Invest-in-America 5 months ago
MBRX: Ten bucks by day's end, Peeps!!! (IMO, that is.) I posit that Planet Earth is just beginning to understand what this Firm is attempting to do for we H. sapiens!!!

👍️0
Invest-in-America Invest-in-America 5 months ago
MBRX: I grabbed mine about 20-minutes ago via my 'E-Turd' acct., & it wasn't easy to snag. (I'm not enamored of "Direct Offerings", etc., like they did late yesterday --- but we'll see what happens here.)
👍️0
madras50 madras50 5 months ago
sweet. i actually managed to scoop up some 1.15 in the AH drop yesterday
👍️0
Invest-in-America Invest-in-America 5 months ago
MBRX: To dah Moooooooooon!!!
👍️0
glenn1919 glenn1919 5 months ago
MBRX..................................https://stockcharts.com/h-sc/ui?s=MBRX&p=W&b=5&g=0&id=p86431144783
👍️0
Invest-in-America Invest-in-America 5 months ago
MBRX: Wrong, Dude!!! Pres. DumbFuck will put a TARIFF on it!!!!
👍️0
Invest-in-America Invest-in-America 5 months ago
MBRX: Maybe $5-$10, tomorrow anybody????
👍️0
TheSprinx TheSprinx 5 months ago
Bid 
👍️0
TheSprinx TheSprinx 5 months ago
Another halt and Biden shows $4.00
👍️0
tedpeele tedpeele 5 months ago
great call.
👍️0
tw0122 tw0122 5 months ago
$3.47!Low float news power .76 to $3s best I can say either it's up to $4.20s next or folks start taking mega profits 
👍️0
TheSprinx TheSprinx 5 months ago
Hey Shorty, how do you like us now??!! 🖕🏽
👍️0
TheFinalCD TheFinalCD 5 months ago
$MBRX 3.09 halted
https://ih.advfn.com/stock-market/NASDAQ/moleculin-biotech-MBRX/stock-news/95429155/form-8-k-current-report
👍️0
makinezmoney makinezmoney 5 months ago
$MBRX: HOTTTTTTtttttttttt Tamales.............. now $3.10 !!!!!!!!!

A bagger already since my 1st post here


Whatta BANNGER !!!!!!!!!

52wk high on this is $10 going back to last March 1, 2024 !!!!!!!!!!!!

No reason why it can't retest that with this news today.


GO $MBRX
👍️0
weedtrader420 weedtrader420 5 months ago
WOOHOOOOOOOOOOOOOOOOOOOO🥳🥳🥳🥳🥳🥳🥳🥳🥳🥳
👍️0
glenn1919 glenn1919 5 months ago
MBRX....................................https://stockcharts.com/h-sc/ui?s=MBRX&p=W&b=5&g=0&id=p86431144783
👍️0
makinezmoney makinezmoney 5 months ago
$MBRX: WOW............. now $1.66


Massive move from $0.44............ wish I saw it earlier.


GO $MBRX
👍️0
TheSprinx TheSprinx 5 months ago
Short squeeze?!
👍️0
georgie18 georgie18 5 months ago
MBRX...Already out here...🥳
👍️0

Your Recent History

Delayed Upgrade Clock